Steels know the parameters of the project announced in the spring of "Voronezhmedsteklo" for the construction of the Voronezh region in a full production cycle for the production of glass of the first hydrolytic class for the pharmaceutical industry.According to investors, the output will reach 17.5 million tons of glass per year. Total investments - 3.5 billion rubles., Return on the project, according to the business plan, will take 4.8 years. Analysts generally are promising and viable project, but before the start of large-scale investments recommend that investors consider a market and competitive pricing.
That of "Voronezhmedsteklo" ("MCG Voronezh") intends to build on the region full production cycle for the production of glass of the first hydrolytic class for the pharmaceutical industry, it became known in March of this year. It claimed that the plant will be processing of natural raw materials into finished products: ampoules, bottles, vials for pharmaceutical industry. However, the parameters of the project were not known until now. The planned production capacity - 17.5 thousand tons of glass per year. Total investments - 3.5 billion rubles., A business plan is a 38% internal rate of return, payback period - 4.8 years. As explained "" CEO "Voronezhfarmstekla" Sergei Sklyarov, co-investing in the project is the JSC "International Potash Company" under the "project financing from the Central Black Earth Savings Bank of the Russian Federation." According to the project, sand production will be purchased first in Ulyanovsk (Ulyanovsk region) and Novoselkovskoe GOK (Kharkiv region, Ukraine), it is planned to move to its own raw material base, which is regarded as a deposit in Strelitz Bogdanov's Voronezh region.
Believe in Voronezh oblpravitelstve, the project "aims at the implementation of the first in Russia experience a progressive transfer of foreign technology in industrial production of special types of glass." Its implementation will allow to satisfy the domestic market domestic products of the glass of the first hydrolytic class, and drug manufacturers to provide a modern packaging (ampoules and vials). Thus, the generated output is aimed at import substitution, which is consistent with the state policy in the field of pharmaceutical and medpromyshlennosti defined in the Strategy of pharmaceutical industry of the Russian Federation for the period up to 2020.
JSC "Voronezhmedsteklo" (JSC "EM-SI-Voronezh") was registered in March 2010 as a manufacturer of flat glass, fiber glass, hollow glass, etc. According kartoteka.ru, co-owners of the company are the Vadim Zubarev and Alexander Danilov (by 34%), and Sergei Sklyarov, Andrey Lazarev, Alex Leukhin and Vadim Green (8%).
Vladimir Chufenev, General Director of JSC "Voronezh Industrial Corporation," Managing infrastructure facilities and the property complex of the industrial park, "Maslowski", told "Kommersant" that the investment project is considered twice in the department of economic development, and at the last meeting, on 10 July, it was decided to submit it to to the interdepartmental committee in early August. "Under him already allocated land area of ??20 hectares, but it is made available to investors only after the committee's decision", - said Vladimir Chufenev. Recall that in the region is the largest company in the pharmaceutical industry of "Veropharm", which is also based in the "Maslovskiy." On his plans to build a plant for the production of finished pharmaceutical products and cosmetics in mednaznacheniya "Maslovskiy" became known in March 2011. However, according to the source "b" in the company, it is now "going through hard times," and begin to implement the project in a hurry.
Among the major Russian consumers of medical glass - of "" Moshimfarmpreparaty "them. NA Semashko "NPO" Microgen ". Their level of consumption up to 6 billion ampoules or vials per year. They are involved in many state programs on drugs for life-support, which can not be rolled back, so the collapse of the market is not expected, certain investors. Plus is the expansion of foreign manufacturers on the market, which are also in need of medical glass. According to the investors themselves, the market requires about 60 tons Medsteklo. The main competitor of the enterprise may be of "Kurskmedsteklo" - one of the largest manufacturers of ampoules in Russia and the CIS with production capacity of 450 million pieces per year, located in Kursk.
Managing partner of the Institute of Experimental Economics and Finance MSU Veronica Peshkov believes that investors have chosen promising line of business, but advises before deciding on the scale investments, the most detailed pool of potential customers, especially in the presence of the project: "Investors argue that the project has a market , especially in the Russian manufacturers. However, the rate for higher quality as a competitive advantage and can not work. The domestic pharma market by more than half focused on the production of generic drugs (similar to expensive drugs. - "B"), and not original products and the quality of the glass for them may not be important. " CEO of information-analytical agency AK & M Zoe Lar'kina also studied the draft "Voronezhmedstekla", believes that his study "highly commendable" and "very interesting from the point of view of import substitution." However, according to Mrs. Larkin, "may be a spoiler for the difficult times being experienced by the Russian pharmaceutical market today." "The future of the project will be only if pricing will be competitive producers," - she added.
